← Back to Search

Thrombolytic Agent

Alteplase for Intra-Abdominal Abscess

Phase 2
Waitlist Available
Led By Hyo-Chun Yoon, MD, PhD
Research Sponsored by Kaiser Permanente
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 days
Awards & highlights
All Individual Drugs Already Approved

Summary

Intracavitary injection of low dose alteplase into loculated abdominopelvic abscesses will reduce the duration of percutaneous drainage and increase the proportion of successful drainages.

Eligible Conditions
  • Intra-Abdominal Abscess
  • Abdominal Abscess
  • Pelvic Abscess

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Duration (in Days) of Percutaneous Drainage.
Percentage of Loculated Abscesses Which Completely Resolve With Percutaneous Drainage Alone at the First Follow-up CT Scan Performed 3 Days After Initial Drain Placement

Side effects data

From 2017 Phase 4 trial • 81 Patients • NCT02159521
10%
Deep vein thrombosis
8%
Nausea
6%
Procedural haemorrhage
4%
Pain in extremity
4%
Back pain
3%
Pruritus
3%
Asthma
3%
Haematoma
3%
Anaemia
3%
Bradycardia
3%
Anxiety
3%
Contusion
3%
Haematuria
1%
Hypertension
1%
Pelvic venous thrombosis
1%
Lactic acidosis
1%
Blood fibrinogen decreased
1%
Constipation
1%
Dizziness
1%
Oxygen saturation decreased
1%
Upper gastrointestinal haemorrhage
1%
Sinusitis
1%
Epistaxis
1%
Migraine
1%
Drug hypersensitivity
1%
Insomnia
1%
Atrial fibrillation
1%
Haemoptysis
1%
Joint effusion
1%
Groin pain
1%
Pneumonia aspiration
1%
Post procedural haemorrhage
1%
Oedema
1%
Injection site haemorrhage
1%
Abdominal pain
1%
Uterine haemorrhage
1%
Cardiac failure congestive
1%
Pulmonary embolism
1%
Ecchymosis
1%
Osteomyelitis
1%
Septic shock
1%
Haemorrhage
1%
Rash
1%
Venous occlusion
1%
Hypoaesthesia
1%
Dyspnoea
1%
Ventricular extrasystoles
1%
Urinary tract infection
1%
Heparin-induced thrombocytopenia
1%
Skin ulcer
1%
Dysuria
1%
Squamous cell carcinoma
100%
80%
60%
40%
20%
0%
Study treatment Arm
EkoSonic® Endovascular System

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AlteplaseExperimental Treatment1 Intervention
Multiple Alteplase injection into the abscess collection to improve percutaneous drainage
Group II: SalinePlacebo Group1 Intervention
Multiple normal saline injection into the abscess collection to improve percutaneous drainage
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Alteplase
FDA approved

Find a Location

Who is running the clinical trial?

Kaiser PermanenteLead Sponsor
554 Previous Clinical Trials
27,731,734 Total Patients Enrolled
Genentech, Inc.Industry Sponsor
1,564 Previous Clinical Trials
570,626 Total Patients Enrolled
Hyo-Chun Yoon, MD, PhDPrincipal InvestigatorKaiser Permanente Hawaii
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top